← All trials
NCT05196945
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Feb 28, 2023
- First posted
- Jan 19, 2022
- Last posted
- Feb 17, 2022
- Enrollment
- 316
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- First People's Hospital of FoshanCollaborator
- Shengjing HospitalCollaborator
- Dalian Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Southern Medical UniversityCollaborator
- Southern Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Guangzhou Panyu Central HospitalCollaborator
- Shantou UniversityCollaborator
- People's Hospital of ChongqingCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.